Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Also, FYI Angiochem has already passed Phase 2 trial for ANG1005, a peptide-drug conjugate containing paclitaxel covalently linked to the Angiopep-2 peptide. An October 2016 news release suggested that they plan to start Phase 3 for ANG1005 in 2017. I wonder where this stands.....
